<p>Agios Pharmaceuticals, Inc.（纳斯达克代码：AGIO - 获取免费报告）的股票在周五交易中下跌了 5.3%。该股最低交易价为 27.55 美元，最后交易价为 27.6350 美元。在午盘交易中，约有 772,530 股被交易，较平均每日交易量 904,194 股下降了 15%。该股此前收盘价为 29.17 美元。</p>
<p>获取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该公司发布了报告。加拿大皇家银行将 Agios Pharmaceuticals 的评级从 “跑赢大盘” 下调至 “行业表现”，并在 11 月 19 日的报告中将其股票目标价从 57.00 美元下调至 28.00 美元。高盛集团在 11 月 20 日的报告中将 Agios Pharmaceuticals 的股票目标价从 40.00 美元下调至 25.00 美元，并对该股给予 “中性” 评级。华尔街 Zen 在 11 月 22 日的研究报告中将 Agios Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Leerink Partners 在 11 月 20 日的研究报告中将 Agios Pharmaceuticals 的股票评级从 “持有” 上调至 “强烈买入”。最后，Weiss Ratings 在周一的研究报告中重申了对 Agios Pharmaceuticals 的 “卖出（d）” 评级。一位分析师给予该股 “强烈买入” 评级，六位给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 38.89 美元。</p>
<p><strong>查看我们对 AGIO 的最新股票分析</strong></p>
<h2>Agios Pharmaceuticals 股票表现</h2>
<p>该公司的 50 日移动平均线为 34.03 美元，200 日移动平均线为 36.26 美元。该公司的市值为 16.1 亿美元，市盈率为-3.95，贝塔值为 0.87。</p>
<p>Agios Pharmaceuticals（纳斯达克代码：AGIO - 获取免费报告）最近一次公布财报是在 10 月 30 日，生物制药公司报告该季度每股收益为（1.78 美元），超出市场共识预期的（1.93 美元）0.15 美元。Agios Pharmaceuticals 的净利润率为-895.86%，股本回报率为-28.35%。该公司在该季度的收入为 1288 万美元，而市场共识预期为 1049 万美元。在去年同期，该公司每股收益为 16.22 美元。该公司的季度收入较去年同期增长了 43.3%。研究分析师预测 Agios Pharmaceuticals, Inc.在本财年将发布-6.85 美元的每股收益。</p>
<h2>内部交易活动</h2>
<p>在其他消息中，内部人士 Sarah Gheuens 在 10 月 27 日的交易中出售了 3302 股公司股票。这些股票以平均价格 43.92 美元出售，总价值为 145,023.84 美元。出售后，该内部人士在公司持有 61,727 股，价值约为 2,711,049.84 美元。这代表其持股减少了 5.08%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。内部人士在过去三个月内共出售了 3902 股公司股票，价值 170,754 美元。目前，内部人士持有该股票的 4.30%。</p>
<h2>Agios Pharmaceuticals 的机构交易</h2>
<p>几家机构投资者最近增加或减少了在该公司的持股。Marshall Wace LLP 在第二季度将其在 Agios Pharmaceuticals 的持股增加了 31.4%。Marshall Wace LLP 目前持有 684,669 股生物制药公司的股票，价值 22,772,000 美元，此前在上个季度增持了 163,796 股。Assenagon Asset Management S.A.在第三季度获得了 Agios Pharmaceuticals 的新头寸，价值 2,696,000 美元。Frazier Life Sciences Management L.P.在第二季度将其在 Agios Pharmaceuticals 的持股增加了 19.6%。Frazier Life Sciences Management L.P.目前持有 1,279,754 股生物制药公司的股票，价值 42,565,000 美元，此前在该期间增持了 209,900 股。Connor Clark &amp; Lunn Investment Management Ltd.在第二季度将其在 Agios Pharmaceuticals 的持股增加了 30.7%。Connor Clark &amp; Lunn Investment Management Ltd.目前持有 505,225 股生物制药公司的股票，价值 16,804,000 美元，此前在上个季度增持了 118,702 股。最后，Boothbay Fund Management LLC 在第二季度将其在 Agios Pharmaceuticals 的持股增加了 71.1%。Boothbay Fund Management LLC 目前持有 447,019 股生物制药公司的股票，价值 14,868,000 美元，此前在该期间增持了 185,798 股。</p>
<h2>关于 Agios Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Agios Pharmaceuticals, Inc 是一家生物制药公司，成立于 2008 年，源于 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司总部位于马萨诸塞州剑桥，Agios 专注于理解和针对细胞代谢，以开发用于癌症和罕见遗传疾病的新疗法。该公司的科学平台整合了基因组发现、代谢分析和精准医学方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
<p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Agios Pharmaceuticals 更好</li>
<li>NNVC 以 7 美元的估值，可能在 2026 年颠覆生物技术领域</li>
<li>BNZI 发布创纪录的第三季度收入 – 看看是什么推动了它。</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>[如何] 认领你在 SpaceX 的 IPO 前股份！</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Agios 制药吗？</h2>
<p>在考虑 Agios 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Agios 制药并不在名单上。</p>
<p>虽然 Agios 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Agios制药

<p>Agios 制药（NASDAQ:AGIO）股价在交易中下跌了 5.3%，最低交易价格为 27.55 美元。分析师的评级不一，有些下调了该股票的评级，而另一些则上调了。公司报告的收益超出预期，但内部人士一直在出售股票。机构投资者已调整其持股，有些增加了持股，而另一些则减少了持股</p>

<p>Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) were down 5.3% during trading on Friday . The stock traded as low as $27.55 and last traded at $27.6350. Approximately 772,530 shares were traded during mid-day trading, a decline of 15% from the average daily volume of 904,194 shares. The stock had previously closed at $29.17.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc.（纳斯达克代码：AGIO - 获取免费报告）的股票在周五交易中下跌了 5.3%。该股最低交易价为 27.55 美元，最后交易价为 27.6350 美元。在午盘交易中，约有 772,530 股被交易，较平均每日交易量 904,194 股下降了 15%。该股此前收盘价为 29.17 美元。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada cut Agios Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;sector perform&#34; rating and decreased their price objective for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. The Goldman Sachs Group cut their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, November 20th. Wall Street Zen cut shares of Agios Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 22nd. Leerink Partnrs raised shares of Agios Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, November 20th. Finally, Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Agios Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $38.89.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发布了报告。加拿大皇家银行将 Agios Pharmaceuticals 的评级从 “跑赢大盘” 下调至 “行业表现”，并在 11 月 19 日的报告中将其股票目标价从 57.00 美元下调至 28.00 美元。高盛集团在 11 月 20 日的报告中将 Agios Pharmaceuticals 的股票目标价从 40.00 美元下调至 25.00 美元，并对该股给予 “中性” 评级。华尔街 Zen 在 11 月 22 日的研究报告中将 Agios Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Leerink Partners 在 11 月 20 日的研究报告中将 Agios Pharmaceuticals 的股票评级从 “持有” 上调至 “强烈买入”。最后，Weiss Ratings 在周一的研究报告中重申了对 Agios Pharmaceuticals 的 “卖出（d）” 评级。一位分析师给予该股 “强烈买入” 评级，六位给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 38.89 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on AGIO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AGIO 的最新股票分析</strong></p>
</div><h2>Agios Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 股票表现</h2>
</div><p>The firm has a fifty day moving average of $34.03 and a 200 day moving average of $36.26. The firm has a market capitalization of $1.61 billion, a PE ratio of -3.95 and a beta of 0.87.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 34.03 美元，200 日移动平均线为 36.26 美元。该公司的市值为 16.1 亿美元，市盈率为-3.95，贝塔值为 0.87。</p>
</div><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The business had revenue of $12.88 million during the quarter, compared to the consensus estimate of $10.49 million. During the same period in the prior year, the firm earned $16.22 earnings per share. The business's quarterly revenue was up 43.3% compared to the same quarter last year. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals（纳斯达克代码：AGIO - 获取免费报告）最近一次公布财报是在 10 月 30 日，生物制药公司报告该季度每股收益为（1.78 美元），超出市场共识预期的（1.93 美元）0.15 美元。Agios Pharmaceuticals 的净利润率为-895.86%，股本回报率为-28.35%。该公司在该季度的收入为 1288 万美元，而市场共识预期为 1049 万美元。在去年同期，该公司每股收益为 16.22 美元。该公司的季度收入较去年同期增长了 43.3%。研究分析师预测 Agios Pharmaceuticals, Inc.在本财年将发布-6.85 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, insider Sarah Gheuens sold 3,302 shares of the company's stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the sale, the insider owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 3,902 shares of company stock valued at $170,754 in the last three months. 4.30% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Sarah Gheuens 在 10 月 27 日的交易中出售了 3302 股公司股票。这些股票以平均价格 43.92 美元出售，总价值为 145,023.84 美元。出售后，该内部人士在公司持有 61,727 股，价值约为 2,711,049.84 美元。这代表其持股减少了 5.08%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。内部人士在过去三个月内共出售了 3902 股公司股票，价值 170,754 美元。目前，内部人士持有该股票的 4.30%。</p>
</div><h2>Institutional Trading of Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 的机构交易</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP raised its stake in Agios Pharmaceuticals by 31.4% during the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company's stock valued at $22,772,000 after acquiring an additional 163,796 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at $2,696,000. Frazier Life Sciences Management L.P. increased its position in shares of Agios Pharmaceuticals by 19.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company's stock valued at $42,565,000 after purchasing an additional 209,900 shares during the period. Connor Clark &amp; Lunn Investment Management Ltd. raised its stake in shares of Agios Pharmaceuticals by 30.7% in the 2nd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 505,225 shares of the biopharmaceutical company's stock worth $16,804,000 after buying an additional 118,702 shares in the last quarter. Finally, Boothbay Fund Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 71.1% in the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company's stock valued at $14,868,000 after buying an additional 185,798 shares during the period.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了在该公司的持股。Marshall Wace LLP 在第二季度将其在 Agios Pharmaceuticals 的持股增加了 31.4%。Marshall Wace LLP 目前持有 684,669 股生物制药公司的股票，价值 22,772,000 美元，此前在上个季度增持了 163,796 股。Assenagon Asset Management S.A.在第三季度获得了 Agios Pharmaceuticals 的新头寸，价值 2,696,000 美元。Frazier Life Sciences Management L.P.在第二季度将其在 Agios Pharmaceuticals 的持股增加了 19.6%。Frazier Life Sciences Management L.P.目前持有 1,279,754 股生物制药公司的股票，价值 42,565,000 美元，此前在该期间增持了 209,900 股。Connor Clark &amp; Lunn Investment Management Ltd.在第二季度将其在 Agios Pharmaceuticals 的持股增加了 30.7%。Connor Clark &amp; Lunn Investment Management Ltd.目前持有 505,225 股生物制药公司的股票，价值 16,804,000 美元，此前在上个季度增持了 118,702 股。最后，Boothbay Fund Management LLC 在第二季度将其在 Agios Pharmaceuticals 的持股增加了 71.1%。Boothbay Fund Management LLC 目前持有 447,019 股生物制药公司的股票，价值 14,868,000 美元，此前在该期间增持了 185,798 股。</p>
</div><h2>About Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Agios Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc 是一家生物制药公司，成立于 2008 年，源于 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司总部位于马萨诸塞州剑桥，Agios 专注于理解和针对细胞代谢，以开发用于癌症和罕见遗传疾病的新疗法。该公司的科学平台整合了基因组发现、代谢分析和精准医学方法，以识别和推进能够纠正或利用代谢功能障碍的小分子候选药物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要产品是针对特定癌症突变的 IDH（异柠檬酸脱氢酶）抑制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
<li>With a $7 Valuation, NNVC Could Disrupt the Biotech Space in 2026</li>
<li>BNZI Posts Record Q3 Revenue – See What’s Driving It.</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>[How To] Claim Your Pre-IPO Stake In SpaceX!</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Agios Pharmaceuticals 更好</li>
<li>NNVC 以 7 美元的估值，可能在 2026 年颠覆生物技术领域</li>
<li>BNZI 发布创纪录的第三季度收入 – 看看是什么推动了它。</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>[如何] 认领你在 SpaceX 的 IPO 前股份！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Agios 制药吗？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Agios 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Agios 制药并不在名单上。</p>
</div><p>While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Agios 制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Agios 制药（NASDAQ:AGIO）的股价下跌了 5.3% - 你是否应该卖出？